The Effect of Adding Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Undetectable Pretreatment Epstein-Barr Virus DNA
PURPOSE: To assess the effect of adding neoadjuvant chemotherapy (NACT) to concurrent chemoradiotherapy (CCRT) in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) and undetectable pretreatment Epstein-Barr virus (pEBV) DNA. MATERIALS AND METHODS: We enrolled 639 NPC patients with stage II to IVB and undetectable pEBV DNA to receive CCRT with or without NACT. Radiotherapy was 2.0 to 2.27 Gy per fraction with five daily fractions per week for 6 to 7 weeks to the primary tumor and 62 to 70 Gy to the involved neck area. NACT was cisplatin (80-100mg/m(2) day 1) and 5-fluorouracil (800-1000 mg/m(2), 120-hour continuous intravenous infusion) every 3 weeks for two or three cycles. CCRT was cisplatin (80-100 mg/m(2) day 1) every 3 weeks for three cycles. RESULTS: For all patients, the 5-year overall survival (OS), locoregional relapse-free survival (LRFS), distantmetastasis-free survival (DMFS), and progression-free survival (PFS) rates were 91.9%, 92.2%, 95.0%, and 86.4%, respectively. There was no significant difference in OS (5-year OS 90.8% [NACT + CCRT group] vs 92.7% [CCRT alone]; hazard ratio [HR] 1.24; P = .486), LRFS (HR 1.13, 95% confidence interval [CI] 0.59-2.14, P = .715), DMFS (HR 0.78, 95% CI 0.34-1.78, P = .554), or PFS (HR 1.21, 95% CI 0.75-1.95, P = .472). CONCLUSION: CCRT with or without NACT produced a good treatment outcome in patients with locoregionally advanced NPC and undetectable pEBV DNA, but NACT before CCRT did not significantly improve survival rates.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81372409, 81402532]; Sun Yat-sen University Clinical Research 5010 Program [2012011]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|3 区医学
小类|3 区肿瘤学
最新[2023]版：
大类|2 区医学
小类|3 区肿瘤学
第一作者：
第一作者机构：[1]State Key Lab Oncol South, Hong Kong, Hong Kong, Peoples R China;[2]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China;[3]Sun Yat Sen Univ, Canc Ctr, Dept Nasopharyngeal Carcinoma, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China;
通讯作者：
通讯机构：[1]State Key Lab Oncol South, Hong Kong, Hong Kong, Peoples R China;[2]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China;[8]Sun Yat Sen Univ, Canc Ctr, Dept Radiat Oncol, Guangzhou 510060, Guangdong, Peoples R China;[9]Sun Yat Sen Univ, Dept Radiat Oncol,Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China;[10]Univ Canc Ctr, Sun Yat Sen Dept Nasopharyngeal Carcinoma, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China
推荐引用方式(GB/T 7714)：
Jin Ya-Nan,Yao Ji-Jin,Wang Si-Yang,et al.The Effect of Adding Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Undetectable Pretreatment Epstein-Barr Virus DNA[J].TRANSLATIONAL ONCOLOGY.2017,10(4):527-534.doi:10.1016/j.tranon.2017.03.007.
APA：
Jin, Ya-Nan,Yao, Ji-Jin,Wang, Si-Yang,Zhang, Wang-Jian,Zhang, Fan...&Sun, Ying.(2017).The Effect of Adding Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Undetectable Pretreatment Epstein-Barr Virus DNA.TRANSLATIONAL ONCOLOGY,10,(4)
MLA：
Jin, Ya-Nan,et al."The Effect of Adding Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Undetectable Pretreatment Epstein-Barr Virus DNA".TRANSLATIONAL ONCOLOGY 10..4(2017):527-534
